Celldex Therapeutics, Inc. (CLDX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Celldex Therapeutics’s revenue went from $7M in fiscal 2016 to $2M in fiscal 2025, a decline of about 15.2% a year.
Net income in fiscal 2025 was -$259M, a net margin of -16748.0%; the best year in this period was 2019 with -$51M.
Over the twelve months to September 30, 2026, revenue was $158000 and net income -$309M.
Free cash flow was -$214M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 881% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158000 | $2M | $7M | $7M | $2M | $5M | $7M | $4M | $10M | $13M | $7M |
| Gross profit | — | $1M | $7M | $7M | $2M | $5M | $7M | $3M | $9M | $12M | $5M |
| Operating income | -$334M | -$287M | -$195M | -$155M | -$115M | -$71M | -$63M | -$55M | -$156M | -$122M | -$133M |
| Net income | -$309M | -$259M | -$158M | -$141M | -$112M | -$71M | -$60M | -$51M | -$151M | -$93M | -$129M |
| EPS (diluted) | $-4.31 | $-3.90 | $-2.45 | $-2.92 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-10.86 | $-18.99 |
| R&D | $283M | $245M | $164M | $118M | $82M | $53M | $43M | $43M | $66M | $96M | $103M |
| Revenue growth | — | −78.0% | +2.0% | +192.0% | −49.3% | −37.3% | +107.6% | −62.5% | −25.1% | +87.8% | +23.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$252M | -$211M | -$158M | -$107M | -$104M | -$61M | -$40M | -$46M | -$75M | -$100M | -$113M |
| Capital spending | -$8M | -$3M | -$2M | -$2M | -$2M | -$1M | -$2M | -$731000 | -$813000 | -$2M | -$3M |
| Free cash flow | -$260M | -$214M | -$160M | -$109M | -$106M | -$62M | -$42M | -$47M | -$76M | -$102M | -$116M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $37M | $36M | $34M | $24M | $16M | $9M | $4M | $5M | $8M | $12M | $15M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $519M | $725M | $424M | $305M | $408M | $194M | $64M | $94M | $139M | $190M |
| Debt | — | $2M | $4M | $3M | $4M | $3M | $3M | $4M | — | — | — |
| Equity | — | $527M | $747M | $429M | $326M | $419M | $209M | $94M | $124M | $236M | $265M |
| Total assets | — | $583M | $792M | $466M | $353M | $445M | $236M | $123M | $156M | $316M | $383M |
| Shares (diluted) | 79M | 66M | 64M | 48M | 47M | 43M | 30M | 15M | 10M | 9M | 7M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 87.1% | 97.2% | 95.6% | 95.8% | 97.9% | 97.3% | 97.2% | 92.7% | 94.5% | 76.4% |
| Operating margin | -211684.8% | -18599.8% | -2778.9% | -2245.3% | -4889.0% | -1531.8% | -854.1% | -1540.2% | -1640.1% | -953.7% | -1958.7% |
| Net margin | -195608.9% | -16748.0% | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% |
| FCF margin | -164391.8% | -13829.1% | -2274.9% | -1585.2% | -4478.6% | -1336.4% | -565.6% | -1319.5% | -797.3% | -798.2% | -1706.3% |
| ROIC | — | -54.3% | -26.0% | -35.8% | -27.6% | -16.8% | -29.2% | -44.5% | -125.5% | -40.8% | -39.6% |
| ROE | — | -49.1% | -21.1% | -33.0% | -34.4% | -16.8% | -28.5% | -54.1% | -121.9% | -39.4% | -48.4% |
Frequently asked questions
What is Celldex Therapeutics’s annual revenue?
$2M in fiscal 2025 and $158000 over the twelve months to September 30, 2026.
How much profit does Celldex Therapeutics make?
Net income was -$259M in fiscal 2025 (net margin -16748.0%).
Is Celldex Therapeutics’s revenue growing?
No: revenue fell 78.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.